Caplin Point Laboratories Limited

NSE: CAPLIPOINTHealthcare

Caplin Point Laboratories Limited Share Price & Analysis

₹2362.80+0.44%Updated 28 Oct 2026, 03:30 pm IST
LTP
₹2362.80+0.44%
Open
₹2340.10
High
₹2377.10
Low
₹2330.00
Close
₹2362.80
52W High
₹2991.00
52W Low
₹1500.00
Volume
39K
Lot Size
1
Sector
Healthcare
Market Cap
₹17K Cr
Face Value
₹2
Mid CapNIFTY 500Nifty Smallcap 250

Price Chart

Candle
Range

Fundamentals

P/E
25.40
Sector P/E
50.20
P/B
4.30
EPS
₹84.15
ROE
20.90%
ROCE
24.20%
D/E Ratio
0.00
Div Yield
0.36%
Book Value
₹443.00

Strengths

  • Excellent return on equity (ROE 20.9%)
  • Efficient capital deployment (ROCE 24.2%)
  • Attractively valued vs sector (P/E 25.4x vs industry 50.2x)
  • Virtually debt-free

Concerns

    Peer Comparison

    CompanyCMPMkt CapP/EP/BROE %ROCE %D/E
    SUNPHARMA
    Sun Pharmaceutical Industries Limited
    ₹1,758
    ₹4.2L Cr33.25.051620.50.07
    DIVISLAB
    Divi's Laboratories Limited
    ₹9,559
    ₹2.4L Cr79.815.1516.5220.01
    TORNTPHARM
    Torrent Pharmaceuticals Limited
    ₹4,557
    ₹1.7L Cr79.39.4327.415.20.77
    ZYDUSLIFE
    Zydus Lifesciences Limited
    ₹1,176
    ₹1.1L Cr23.14.3721.221.10.38
    APOLLOHOSP
    Apollo Hospitals Enterprise Limited
    ₹8,137
    ₹1.1L Cr52.812.3521.217.40.88
    CIPLA
    Cipla Limited
    ₹1,366
    ₹1.1L Cr30.23.2111.615.50.01
    LAURUSLABS
    Laurus Labs Limited
    ₹2,182
    ₹1.1L Cr97.422.2218.317.80.46

    Showing 7 peers in the same sector · Sorted by market cap

    Shareholding Pattern

    CAPLIPOINT · as of Mar 2026

    Promoters70.56%
    FII5.73%0.87pp
    DII2.00%0.11pp
    Public21.72%0.76pp
    CategoryDec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
    Promoters70.62%70.62%70.56%70.56%70.56%70.56%
    FII2.84%3.33%3.38%3.71%4.86%5.73%
    DII0.43%1.08%1.49%1.83%2.11%2.00%
    Public26.11%24.95%24.59%23.93%22.48%21.72%

    Corporate Events

    Dividend - Rs 4 Per Share

    Dividend17 Sept 2026

    To consider and approve the financial results for the period ended June 30, 2026 and to recommend final dividend

    Dividend11 Aug 2026

    Interim Dividend - Rs 4 Per Share

    Record: 29 May 2026

    Dividend28 May 2026

    Dividend - Rs 3 Per Share

    Dividend11 Sept 2025

    Interim Dividend - Rs 3 Per Share

    Dividend29 May 2025

    Annual General Meeting

    AGM22 Sept 2024

    Dividend - Rs 2.50 Per Share

    Dividend22 Sept 2024

    Interim Dividend - Rs 2.50 Per Share

    Dividend30 May 2024

    Annual General Meeting/Dividend - Rs 2.50 Per Share

    Dividend13 Sept 2023

    Interim Dividend - Rs 2 Per Share

    Dividend8 Jun 2023

    Latest News

    All news

    Caplin Point Labs reports Q1 FY26 results

    *Caplin Point Labs reports Q1 FY26 results.* The company has submitted its financial results for the quarter ended June 30, 2026. Key numbers including revenue and net profit will be reviewed for performance trends. Results are awaited for detailed analysis. 📊 *STOCKS:* $CAPLIN | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #Earnings

    NSE Filing12 Aug
    High Impact

    Caplin Point publishes statutory notice in newspaper

    *Caplin Point publishes statutory notice in newspaper.* This is a routine corporate disclosure as per regulatory requirements. No financial or operational updates provided. **No material impact** expected on stock performance. 📊 *STOCKS:* $CAPLIN | 🏢 *SECTOR:* Pharma | #LOWIMPACT #Regulatory

    NSE Filing4 Sept
    Low Impact

    Caplin Point Labs shares unchanged after shareholder letter.

    *Caplin Point Labs shares unchanged after shareholder letter.* The company released a 'Letter to Shareholders' via NSE filing, outlining general business updates. No **financial figures** or **strategic shifts** were disclosed. The communication appears routine, with no immediate market-moving details. 📊 *STOCKS:* $CAPLIN | 🏢 *SECTOR:* Pharma | #LOWIMPACT #ShareholderLetter

    NSE Filing4 Sept
    Low Impact

    Caplin Point files Business Responsibility and Sustainability Report

    *Caplin Point files Business Responsibility and Sustainability Report.* This is a routine regulatory disclosure under BRSR norms. No financial or operational updates were included. Such filings are mandatory for specified companies. 📊 *STOCKS:* $CAPLIN | 🏢 *SECTOR:* Pharma | #LOWIMPACT #Sustainability

    NSE Filing3 Sept
    Low Impact

    Caplin Point Laboratories to hold shareholder meeting on Sept 25, 2026

    *Caplin Point Laboratories to hold shareholder meeting on Sept 25, 2026.* The event is a routine corporate disclosure with no immediate financial implications. No major strategic decisions or announcements are indicated in the filing. Investors may anticipate updates on company operations or governance. 📊 *STOCKS:* CAPLIN | 🏢 *SECTOR:* Pharma | #LOWIMPACT #ShareholderMeeting

    NSE Filing3 Sept
    Low Impact

    Caplin Point Labs shares rise on investor presentation

    *Caplin Point Labs shares rise on investor presentation.* The company shared an investor presentation highlighting its recent performance and strategic outlook. While no major financial figures were disclosed, the update included pipeline updates and market expansion plans. The stock reacted positively despite absence of hard earnings data. 📊 *STOCKS:* $CAPLIN | 🏢 *SECTOR:* Pharma | #LOWIMPACT #Pharma

    NSE Filing12 Aug
    Low Impact

    Caplin Point declares final dividend of ₹4 per share

    *Caplin Point declares final dividend of ₹4 per share.* The company recommended a final dividend of **₹4 per equity share** for the financial year, to be paid on August 12, 2026. This follows its regular dividend distribution policy, signaling stable shareholder returns. The announcement was made via an NSE corporate filing. 📊 *STOCKS:* $CAPLIN | 🏢 *SECTOR:* Pharma | #LOWIMPACT #Dividend

    NSE Filing12 Aug
    Low Impact

    Caplin Point declares dividend record date

    *Caplin Point declares dividend record date.* The company has set **18-Sep-2026** as the record date for dividend distribution. Shareholders registered on this date will be eligible for the payout. Final dividend amount and payment date will be announced later. 📊 *STOCKS:* $CAPLIN | 🏢 *SECTOR:* Pharma | #LOWIMPACT #Dividend

    NSE Filing12 Aug
    Low Impact

    Caplin Point Labs to host analyst and investor call.

    *Caplin Point Labs to host analyst and investor call.* The company announced a schedule for its upcoming investor interaction. Details on business performance and strategy may be discussed. No financial figures or major announcements disclosed. 📊 *STOCKS:* CAPLIN | 🏢 *SECTOR:* Pharma | #LOWIMPACT #InvestorMeet

    NSE Filing30 Jul
    Low Impact

    Financials

    Quarterly Results

    MetricMar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024
    Revenue
    ₹600 Cr
    10.5%
    ₹543 Cr
    1.7%
    ₹534 Cr
    4.7%
    ₹510 Cr
    1.6%
    ₹502 Cr
    1.8%
    ₹493 Cr
    2.1%
    ₹483 Cr
    5.2%
    ₹459 Cr
    Op. Profit
    ₹204 Cr
    7.4%
    ₹190 Cr
    0.5%
    ₹189 Cr
    6.2%
    ₹178 Cr
    6.0%
    ₹168 Cr
    3.7%
    ₹162 Cr
    1.8%
    ₹165 Cr
    8.6%
    ₹152 Cr
    OPM
    34.0%
    2.9%
    35.0%
    0.0%
    35.0%
    0.0%
    35.0%
    6.1%
    33.0%
    0.0%
    33.0%
    2.9%
    34.0%
    3.0%
    33.0%
    Net Profit
    ₹173 Cr
    4.2%
    ₹166 Cr
    3.8%
    ₹160 Cr
    6.0%
    ₹151 Cr
    4.1%
    ₹145 Cr
    3.6%
    ₹140 Cr
    6.9%
    ₹131 Cr
    4.8%
    ₹125 Cr
    EPS (₹)
    22.38
    3.8%
    21.56
    6.1%
    20.32
    1.1%
    20.1
    7.1%
    18.76
    2.6%
    18.28
    6.2%
    17.21
    5.5%
    16.31

    Values in ₹ Cr · Source: Screener.in

    Annual Profit & Loss

    MetricMar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018Mar 2017
    Revenue
    ₹2.2K Cr
    12.9%
    ₹1.9K Cr
    14.3%
    ₹1.7K Cr
    15.5%
    ₹1.5K Cr
    15.6%
    ₹1.3K Cr
    19.6%
    ₹1.1K Cr
    22.9%
    ₹863 Cr
    33.0%
    ₹649 Cr
    20.2%
    ₹540 Cr
    34.3%
    ₹402 Cr
    Expenses
    ₹1.4K Cr
    10.5%
    ₹1.3K Cr
    12.7%
    ₹1.1K Cr
    11.4%
    ₹1.0K Cr
    17.3%
    ₹874 Cr
    19.4%
    ₹732 Cr
    21.4%
    ₹603 Cr
    44.6%
    ₹417 Cr
    20.9%
    ₹345 Cr
    25.0%
    ₹276 Cr
    Op. Profit
    ₹765 Cr
    17.5%
    ₹651 Cr
    17.9%
    ₹552 Cr
    24.9%
    ₹442 Cr
    11.9%
    ₹395 Cr
    20.1%
    ₹329 Cr
    26.5%
    ₹260 Cr
    12.1%
    ₹232 Cr
    19.0%
    ₹195 Cr
    56.0%
    ₹125 Cr
    OPM
    35.0%
    2.9%
    34.0%
    3.0%
    33.0%
    10.0%
    30.0%
    3.2%
    31.0%
    0.0%
    31.0%
    3.3%
    30.0%
    16.7%
    36.0%
    0.0%
    36.0%
    16.1%
    31.0%
    Other Income
    ₹111 Cr
    20.7%
    ₹92 Cr
    39.4%
    ₹66 Cr
    20.0%
    ₹55 Cr
    44.7%
    ₹38 Cr
    65.2%
    ₹23 Cr
    43.9%
    ₹41 Cr
    115.8%
    ₹19 Cr
    46.2%
    ₹13 Cr
    30.0%
    ₹10 Cr
    Interest
    ₹1 Cr
    0.0%
    ₹1 Cr
    0.0%
    ₹1 Cr
    0.0%
    ₹1 Cr
    0.0%
    ₹1 Cr
    50.0%
    ₹2 Cr
    ₹0 Cr
    100.0%
    ₹1 Cr
    0.0%
    ₹1 Cr
    0.0%
    ₹1 Cr
    Depreciation
    ₹73 Cr
    10.6%
    ₹66 Cr
    24.5%
    ₹53 Cr
    17.8%
    ₹45 Cr
    4.3%
    ₹47 Cr
    27.0%
    ₹37 Cr
    15.6%
    ₹32 Cr
    39.1%
    ₹23 Cr
    21.1%
    ₹19 Cr
    46.2%
    ₹13 Cr
    PBT
    ₹803 Cr
    18.6%
    ₹677 Cr
    20.0%
    ₹564 Cr
    25.1%
    ₹451 Cr
    16.8%
    ₹386 Cr
    22.9%
    ₹314 Cr
    16.7%
    ₹269 Cr
    18.5%
    ₹227 Cr
    20.7%
    ₹188 Cr
    55.4%
    ₹121 Cr
    Tax %
    19.0%
    5.0%
    20.0%
    11.1%
    18.0%
    12.5%
    16.0%
    20.0%
    20.0%
    0.0%
    20.0%
    0.0%
    20.0%
    9.1%
    22.0%
    4.3%
    23.0%
    9.5%
    21.0%
    Net Profit
    ₹650 Cr
    20.1%
    ₹541 Cr
    17.4%
    ₹461 Cr
    22.3%
    ₹377 Cr
    22.4%
    ₹308 Cr
    22.7%
    ₹251 Cr
    16.7%
    ₹215 Cr
    21.5%
    ₹177 Cr
    22.1%
    ₹145 Cr
    51.0%
    ₹96 Cr
    EPS (₹)
    84.36
    19.6%
    70.56
    17.2%
    60.19
    21.4%
    49.57
    25.3%
    39.56
    23.5%
    32.03
    12.7%
    28.42
    21.7%
    23.35
    21.9%
    19.15
    51.4%
    12.65
    Div Payout
    9.0%
    12.5%
    8.0%
    0.0%
    8.0%
    11.1%
    9.0%
    10.0%
    10.0%
    11.1%
    9.0%
    0.0%
    9.0%
    0.0%
    9.0%
    10.0%
    10.0%
    16.7%
    12.0%

    Values in ₹ Cr · Source: Screener.in

    Balance Sheet

    ItemMar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018Mar 2017
    Liabilities
    Equity Capital
    ₹15 Cr
    0.0%
    ₹15 Cr
    0.0%
    ₹15 Cr
    0.0%
    ₹15 Cr
    0.0%
    ₹15 Cr
    0.0%
    ₹15 Cr
    0.0%
    ₹15 Cr
    0.0%
    ₹15 Cr
    0.0%
    ₹15 Cr
    0.0%
    ₹15 Cr
    Reserves
    ₹3.4K Cr
    28.1%
    ₹2.6K Cr
    25.7%
    ₹2.1K Cr
    26.4%
    ₹1.6K Cr
    31.7%
    ₹1.3K Cr
    31.2%
    ₹954 Cr
    11.2%
    ₹858 Cr
    47.4%
    ₹582 Cr
    66.8%
    ₹349 Cr
    66.2%
    ₹210 Cr
    Borrowings
    ₹221 Cr
    0.5%
    ₹222 Cr
    1.4%
    ₹219 Cr
    1.4%
    ₹222 Cr
    1.4%
    ₹219 Cr
    6.8%
    ₹235 Cr
    108.0%
    ₹113 Cr
    213.9%
    ₹36 Cr
    3500.0%
    ₹1 Cr
    0.0%
    ₹1 Cr
    Other Liabilities
    ₹446 Cr
    26.7%
    ₹352 Cr
    7.4%
    ₹380 Cr
    24.6%
    ₹305 Cr
    22.0%
    ₹250 Cr
    57.2%
    ₹159 Cr
    14.4%
    ₹139 Cr
    27.5%
    ₹109 Cr
    19.9%
    ₹136 Cr
    2.3%
    ₹133 Cr
    Total Liabilities
    ₹4.0K Cr
    25.9%
    ₹3.2K Cr
    18.9%
    ₹2.7K Cr
    23.1%
    ₹2.2K Cr
    26.2%
    ₹1.7K Cr
    27.3%
    ₹1.4K Cr
    21.1%
    ₹1.1K Cr
    51.5%
    ₹743 Cr
    48.6%
    ₹500 Cr
    39.7%
    ₹358 Cr
    Assets
    Fixed Assets
    ₹580 Cr
    6.2%
    ₹546 Cr
    20.5%
    ₹453 Cr
    61.8%
    ₹280 Cr
    2.4%
    ₹287 Cr
    5.9%
    ₹305 Cr
    12.1%
    ₹272 Cr
    19.8%
    ₹227 Cr
    34.3%
    ₹169 Cr
    11.2%
    ₹152 Cr
    CWIP
    ₹234 Cr
    62.5%
    ₹144 Cr
    23.1%
    ₹117 Cr
    47.1%
    ₹221 Cr
    1127.8%
    ₹18 Cr
    28.6%
    ₹14 Cr
    30.0%
    ₹20 Cr
    100.0%
    ₹10 Cr
    33.3%
    ₹15 Cr
    400.0%
    ₹3 Cr
    Investments
    ₹859 Cr
    45.6%
    ₹590 Cr
    56.9%
    ₹376 Cr
    33.8%
    ₹281 Cr
    215.7%
    ₹89 Cr
    709.1%
    ₹11 Cr
    82.0%
    ₹61 Cr
    12.9%
    ₹70 Cr
    48.9%
    ₹47 Cr
    176.5%
    ₹17 Cr
    Other Assets
    ₹2.4K Cr
    22.7%
    ₹1.9K Cr
    10.0%
    ₹1.8K Cr
    24.3%
    ₹1.4K Cr
    5.0%
    ₹1.3K Cr
    30.0%
    ₹1.0K Cr
    33.8%
    ₹772 Cr
    77.1%
    ₹436 Cr
    62.1%
    ₹269 Cr
    44.6%
    ₹186 Cr
    Total Assets
    ₹4.0K Cr
    25.9%
    ₹3.2K Cr
    18.9%
    ₹2.7K Cr
    23.1%
    ₹2.2K Cr
    26.2%
    ₹1.7K Cr
    27.3%
    ₹1.4K Cr
    21.1%
    ₹1.1K Cr
    51.5%
    ₹743 Cr
    48.6%
    ₹500 Cr
    39.7%
    ₹358 Cr

    Values in ₹ Cr · Source: Screener.in

    Cash Flow Statement

    ItemMar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018Mar 2017
    Operating CF
    ₹523 Cr
    21.1%
    ₹432 Cr
    35.8%
    ₹318 Cr
    17.3%
    ₹271 Cr
    19.6%
    ₹337 Cr
    25.3%
    ₹269 Cr
    497.8%
    ₹45 Cr
    45.8%
    ₹83 Cr
    25.8%
    ₹66 Cr
    2.9%
    ₹68 Cr
    Investing CF
    ₹-582 Cr
    74.8%
    ₹-333 Cr
    4.4%
    ₹-319 Cr
    47.7%
    ₹-216 Cr
    42.7%
    ₹-377 Cr
    1156.7%
    ₹-30 Cr
    44.4%
    ₹-54 Cr
    46.0%
    ₹-100 Cr
    44.9%
    ₹-69 Cr
    91.7%
    ₹-36 Cr
    Financing CF
    ₹-46 Cr
    21.1%
    ₹-38 Cr
    0.0%
    ₹-38 Cr
    35.7%
    ₹-28 Cr
    31.7%
    ₹-41 Cr
    70.8%
    ₹-24 Cr
    130.0%
    ₹80 Cr
    11.1%
    ₹90 Cr
    850.0%
    ₹-12 Cr
    71.4%
    ₹-7 Cr
    Net Cash Flow
    ₹-105 Cr
    272.1%
    ₹61 Cr
    256.4%
    ₹-39 Cr
    244.4%
    ₹27 Cr
    133.3%
    ₹-81 Cr
    137.7%
    ₹215 Cr
    207.1%
    ₹70 Cr
    4.1%
    ₹73 Cr
    621.4%
    ₹-14 Cr
    156.0%
    ₹25 Cr
    Free Cash Flow
    ₹275 Cr
    14.1%
    ₹241 Cr
    39.3%
    ₹173 Cr
    121.8%
    ₹78 Cr
    68.3%
    ₹246 Cr
    26.2%
    ₹195 Cr
    709.4%
    ₹-32 Cr
    277.8%
    ₹18 Cr
    0.0%
    ₹18 Cr
    58.1%
    ₹43 Cr

    Values in ₹ Cr · Source: Screener.in

    Key Ratios History

    MetricMar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018Mar 2017
    Debtor Days
    138d
    16.0%
    119d
    1.7%
    117d
    19.4%
    98d
    7.7%
    91d
    5.2%
    96d
    1.0%
    97d
    7.8%
    90d
    5.9%
    85d
    183.3%
    30d
    Inventory Days
    181d
    13.8%
    159d
    13.1%
    183d
    15.1%
    159d
    6.7%
    149d
    7.2%
    139d
    33.8%
    210d
    346.8%
    47d
    6.8%
    44d
    0.0%
    44d
    Days Payable
    125d
    21.4%
    103d
    11.2%
    116d
    38.1%
    84d
    17.6%
    102d
    50.0%
    68d
    19.3%
    57d
    25.0%
    76d
    47.2%
    144d
    7.1%
    155d
    Cash Conv. Cycle
    194d
    10.9%
    175d
    4.9%
    184d
    6.4%
    173d
    25.4%
    138d
    16.9%
    166d
    33.9%
    251d
    311.5%
    61d
    481.3%
    -16d
    80.2%
    -81d
    Working Capital Days
    199d
    14.4%
    174d
    4.8%
    166d
    15.3%
    144d
    12.7%
    165d
    13.8%
    145d
    13.2%
    167d
    60.6%
    104d
    121.3%
    47d
    262.1%
    -29d
    ROCE
    24.0%
    7.7%
    26.0%
    0.0%
    26.0%
    0.0%
    26.0%
    7.1%
    28.0%
    0.0%
    28.0%
    15.2%
    33.0%
    26.7%
    45.0%
    28.6%
    63.0%
    7.4%
    68.0%

    Source: Screener.in · Lower days = better efficiency

    About Caplin Point Laboratories Limited

    Caplin Point Laboratories Ltd is engaged in the manufacturing and sourcing of APIs, finished formulations, R&D, clinical research with presence in Latin America, Africa, USA and other nations.[1]

    HealthcarePharmaceuticals & Biotechnology

    Frequently Asked Questions

    What is Caplin Point Laboratories Limited share price today?
    Caplin Point Laboratories Limited (CAPLIPOINT) is currently trading at ₹2,362.8 on NSE, up 0.44% as of the last market session. Prices update daily after market close on MarketNetra.
    Is Caplin Point Laboratories Limited available in F&O (Futures & Options)?
    Yes, Caplin Point Laboratories Limited (CAPLIPOINT) is part of the NSE F&O segment with a lot size of 1 shares. Options are available with monthly expiry contracts. You can track the full option chain and OI analysis on MarketNetra.
    What is Caplin Point Laboratories Limited 52-week high and low?
    Caplin Point Laboratories Limited's 52-week high is ₹2,991 and the 52-week low is ₹1,500. The current price of ₹2,362.8 is 21.0% below the 52W high.
    What is Caplin Point Laboratories Limited P/E ratio?
    Caplin Point Laboratories Limited's current P/E ratio is 25.4. This indicates the market is paying ₹25.4 for every ₹1 of earnings. Compare this to the sector average to assess relative valuation.
    How to trade Caplin Point Laboratories Limited options?
    Caplin Point Laboratories Limited options are traded on NSE with monthly expiry contracts (lot size: 1 shares). To trade CAPLIPOINT options: select your expiry on the option chain page, identify key OI strikes, check the PCR and buildup type on OI analysis, and review FII/DII flows for institutional sentiment before taking a position.